Please assess the completion status of the following clinical trial:

Trial Title: Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults (age \> / = 18 years)~* Diagnosed with one of the following types and stages of tumors: stage III or IV breast cancer; stage III or IV ovarian cancer; stage III or IV bladder cancer; stage III or IV lung cancer; metastatic prostate cancer; stage III or IV diffuse large B-cell lymphoma; multiple myeloma.~* Planned to receive primary prophylaxis with filgrastim biosimilar (EP2006) at the first cycle of chemotherapy (regardless of line of chemotherapy); or receiving secondary prophylaxis with filgrastim biosimilar (EP2006) irrespective of chemotherapy cycle.~* Treated with commercially available filgrastim biosimilar per physician's best clinical judgment and per current European filgrastim biosimilar (EP2006) label.~* Female patients must be either post-menopausal for one year or surgically sterile or using effective contraceptive methods such as barrier method with spermicide or an intra-uterine device. Oral contraceptive use is allowed.~* Informed written consent to participate in the study by patients or their legal guardian.~Exclusion Criteria:~* Patients with myeloid malignancies, with the exception of multiple myeloma.~* Sensitivity to filgrastim biosimilar or any other CSF.~* Hypersensitivity to E. coli-derived proteins.~* Radiotherapy to ≥ 20% of total body bone.~* Infection within two weeks of starting current line of chemotherapy.~* Patients with several medical condition(s) that in view of the investigator prohibits participation in the study.~* Patients with willfully negligent nonadherence to their cancer treatment.~* Use of any investigational agent in the 30 days prior to enrollment.~* Women of childbearing potential not using the contraception method(s) described above.~* Women who are breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Only 1 group (Type: None): Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.

Based on this trial design, predict the completion outcome and termination type (if applicable).